PEPTIDE Registry

Reported experiences and published evidence, kept separate. Explore what people seek, what sources actually study and what remains unknown.

Collection closed. No participant results published.

What would you like to explore?

All groups and topics

Reported-use topics, not evidence grades or diagnoses. The catalog does not cover every possible experience.

Tesamorelin

Editorial context from existing sources; independent scientific review pending. Numerical findings held. A reported-use topic does not establish direct evidence for that aim.

An approved US product context concerns excess abdominal fat in adults with HIV-associated lipodystrophy. Product versions have specific labeling and handling instructions.

The approved population and endpoint cannot be transferred to healthy athletic users. WR/SV presentation differences also defeat universal reconstitution and storage rules.

Sources and proposed-mechanism explanation

Tesamorelin acts in the GH-releasing pathway. A mechanism or a narrow visceral-fat result does not establish a general weight-loss or anti-aging use.

EGRIFTA WR prescribing information, revised March 2025 (new tab)

Practice & Evidence: claims and limits Atlas: molecule science

Collection, review and methods

8 documents · 24 educational profiles · 10 guides. Hosting authorization and reviews remain pending. Drafts are not reports; they do not establish effectiveness or safety.

Methods, consent and privacy

Understanding community practices What each evidence label means Stacks, mixtures and claims of synergy How we handle reported doses and cycles Reading a peptide quality report When someone says it worked Source errors, corrections and retractions From experience to a research question The proposed Community Observation Program Reading future observational results